Study links iPLE in dogs to broader fat-soluble vitamin deficits

A newly published Animals study is sharpening the nutritional picture of inflammatory protein-losing enteropathy in dogs. In the prospective case-control paper, released June 9, researchers found altered serum concentrations of vitamins A, D, and E metabolites in dogs with iPLE compared with healthy controls, and only partial normalization after one month of treatment. That matters because most of the prior veterinary literature has centered on hypovitaminosis D, while this study suggests fat-soluble vitamin disruption in iPLE may be broader. (mdpi.com)

Protein-losing enteropathy is one of the most severe chronic enteropathy phenotypes in dogs and is associated with poorer prognosis than more treatment-responsive forms of disease. Earlier work has established that low serum 25(OH)D is common in canine chronic enteropathy, tends to be lowest in PLE cases, and is linked with inflammatory burden and adverse outcomes. A 2025 Frontiers study, for example, found markedly lower median 25(OH)D concentrations in dogs with PLE than in food-responsive or microbiota-responsive enteropathy, reinforcing the view that vitamin D status tracks with disease severity. (bmcvetres.biomedcentral.com)

The new Animals article builds on that foundation by looking beyond vitamin D alone. According to the journal record, the study was a prospective case-control analysis that compared serum concentrations of vitamins A, D, and E metabolites in dogs with iPLE and healthy controls at diagnosis and again after one month of therapy. The headline finding, as summarized by the journal, is decreased serum concentrations of multiple fat-soluble vitamins in dogs with iPLE, with only partial recovery after treatment. That aligns with a 2024 study in dogs with chronic enteropathy that also described dysregulated fat-soluble vitamin concentrations and found lower 25(OH)D more likely in hypoalbuminemic dogs. (mdpi.com)

Mechanistically, the findings fit with what’s already known about canine enteropathy. Reviews and prior studies suggest several plausible drivers: impaired intestinal fat absorption, mucosal inflammation, altered lipid handling, reduced transport capacity in hypoalbuminemic dogs, and possibly disease-related changes in vitamin-binding proteins or bile acid metabolism. Recent work in canine iPLE has also described microbiome and fecal metabolite abnormalities, adding to the sense that nutrient absorption and intestinal homeostasis are disrupted on several fronts in these patients. (pmc.ncbi.nlm.nih.gov)

Expert consensus is still catching up to what clinicians should do with that information. The ACVIM-endorsed 2026 consensus statement on canine chronic inflammatory enteropathy discusses vitamin assessment and supplementation in selected contexts, but the evidence base remains much stronger for cobalamin than for fat-soluble vitamins. Meanwhile, a randomized, double-blind, placebo-controlled trial published in 2025 found that cholecalciferol treatment can raise serum 25(OH)D concentrations in dogs with PLE, yet broader proof that vitamin D supplementation improves clinical outcomes is still lacking. (pmc.ncbi.nlm.nih.gov)

Why it matters: For practicing veterinarians, this study supports a more nutrition-aware approach to iPLE workups and follow-up. In dogs with severe hypoalbuminemia, chronic diarrhea, weight loss, or poor early response to therapy, fat-soluble vitamin disturbances may be part of the clinical picture, not just an incidental lab finding. At the same time, the paper doesn’t establish that routine screening for vitamins A, D, and E should become standard for every case, nor does it prove that supplementation will improve survival, remission rates, or quality of life. The practical takeaway is probably targeted vigilance: recognize deficiency risk, interpret vitamin results in the context of albumin and inflammatory markers, and avoid assuming normalization will occur quickly once treatment starts. (mdpi.com)

The study also underscores a familiar challenge in enteropathy management: biomarker discovery is moving faster than evidence for intervention. Vitamin D, in particular, looks increasingly useful as a severity-linked marker in canine chronic enteropathy and PLE, but cutoff values, testing cadence, and supplementation protocols remain unsettled. The new fat-soluble vitamin data may push the field toward broader nutritional phenotyping of iPLE, especially in referral settings and academic centers. (frontiersin.org)

What to watch: The next developments to watch are whether follow-up studies define which vitamin abnormalities are clinically actionable, whether supplementation changes outcomes rather than just lab values, and whether future guidelines incorporate fat-soluble vitamin monitoring into iPLE management pathways. (pmc.ncbi.nlm.nih.gov)